scinai logo whitespace border (002).jpg
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023 08:23 ET | Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
scinai logo whitespace border (002).jpg
Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023
October 04, 2023 07:30 ET | Scinai Immunotherapeutics Ltd.
JERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the...
Transparency Market Research
Fusion Inhibitors Market Revenue to Cross USD 7.2 billion by 2031, Exhibiting a 14.2% CAGR: TMR Report
October 04, 2023 03:52 ET | Transparency Market Research
Wilmington, Delaware, United States, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The fusion inhibitors market attained US$ 295.3 million in 2021. The market is likely to...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
October 03, 2023 08:30 ET | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma Biodexa Pharmaceuticals PLC, (Nasdaq:...
Syneos Health_rgb_r.jpg
Syneos Health Appoints Colin Shannon as Chief Executive Officer
October 03, 2023 08:00 ET | Syneos Health, Inc.
Syneos Health today appointed Collin Shannon as its new CEO. Michelle Keefe remains on Company Board and member of its executive leadership team.
Interim results for the six months ended 30 June 2023
September 29, 2023 16:30 ET | Biodexa Pharmaceuticals PLC
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage...
cmi_logo.png
[Latest] Global 3D Printed Medical Implant Market Size/Share Worth USD 9,099.9 Million by 2032 at a 19.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
September 21, 2023 17:30 ET | Custom Market Insights
Austin, TX, USA, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Printed Medical Implant Market Size, Trends and Insights By Component...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
September 21, 2023 08:30 ET | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...
scinai logo whitespace border (002).jpg
Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering
September 15, 2023 09:01 ET | Scinai Immunotherapeutics Ltd.
JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...
Research Nester Logo.jpg
Mammalian Transient Protein Expression Market revenue to exceed USD 650 Million by 2033, says Research Nester
September 14, 2023 05:00 ET | Research Nester
New York, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global mammalian transient protein expression market size is expected to expand at ~8% CAGR from 2023 to 2033. The market is anticipated to garner a...